Intuitive Surgical raised to Buy at UBS citing attractive valuation
naphtalina/iStock via Getty Images


Intuitive Surgical (NASDAQ:ISRG) is trading ~2% higher in the pre-market after UBS upgraded the maker of da Vinci robotic surgical systems to Buy from Neutral, citing a compelling entry point.
The analysts led by Matthew Taylor called it âa quality growth name well positioned for recovery,â noting that the company has recorded a procedure growth of ~14% CAGR even through the pandemic.

Citing a âhigh acuity mixâ and a growth in the use of robotic procedures, the team argues that Intuitive (ISRG) is on track for a quick recovery and projects LDD to MT top-line growth for the company over the next several years as COVID subsides.
In addition, the hospitals will be more inclined to invest in robotics to recover the lost revenue during the pandemic, according to analysts.
The price target raised to $325 from $317 per share implies a premium of ~13% to the last close.
Read more on how Intuitive (ISRG) exceeded expectations with its Q4 2021 financials.